5AM Venture Management LLC Buys Shares of 310,000 Surrozen, Inc. $SRZN

Key Points

• 5AM Venture Management LLC acquired 310,000 shares of Surrozen, Inc., valued at approximately $3,615,000, making it the firm's 22nd largest position.
• Surrozen reported a quarterly earnings per share of ($1.14), surpassing analysts' expectations of ($1.23) by $0.09.
• The stock of Surrozen, Inc. is currently rated as a "buy" by analysts, with an average target price of $38.50.

5AM Venture Management LLC bought a new stake in Surrozen, Inc. (NASDAQ:SRZN - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 310,000 shares of the company's stock, valued at approximately $3,615,000. Surrozen accounts for about 1.4% of 5AM Venture Management LLC's portfolio, making the stock its 22nd largest position. 5AM Venture Management LLC owned about 9.45% of Surrozen as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the business. RA Capital Management L.P. raised its holdings in shares of Surrozen by 140.3% during the first quarter. RA Capital Management L.P. now owns 679,130 shares of the company's stock worth $7,919,000 after acquiring an additional 396,550 shares during the period. Vivo Capital LLC bought a new position in Surrozen during the 1st quarter worth about $3,032,000. Driehaus Capital Management LLC bought a new position in Surrozen during the 1st quarter worth about $2,390,000. Stempoint Capital LP lifted its holdings in shares of Surrozen by 91.7% in the fourth quarter. Stempoint Capital LP now owns 350,573 shares of the company's stock valued at $5,031,000 after purchasing an additional 167,655 shares in the last quarter. Finally, Stonepine Capital Management LLC lifted its holdings in shares of Surrozen by 108.3% in the first quarter. Stonepine Capital Management LLC now owns 285,782 shares of the company's stock valued at $3,332,000 after purchasing an additional 148,582 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors.

Surrozen Price Performance

Surrozen stock traded down $0.25 during trading hours on Friday, hitting $12.20. The company had a trading volume of 10,581 shares, compared to its average volume of 17,021. The firm has a market cap of $104.55 million, a PE ratio of -0.85 and a beta of 0.62. Surrozen, Inc. has a one year low of $5.90 and a one year high of $18.17. The firm has a 50-day moving average of $10.00 and a 200 day moving average of $9.90.

Surrozen (NASDAQ:SRZN - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.09. The company had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 274.42% and a negative return on equity of 545.43%. As a group, research analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $32.00 target price on shares of Surrozen in a report on Monday, May 12th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $38.50.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.